BiotechTube
BlueWillow Biologics

BlueWillow Biologics

Ann Arbor, United States· Est.
bluewillow.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35.6M

Overview

BlueWillow Biologics is a private, clinical-stage biotechnology company pioneering intranasal vaccine development with its NanoVax® adjuvant platform. The company's technology, which originated at the University of Michigan, has demonstrated safety and immunogenicity in multiple Phase 1 human trials, including a recent H5 influenza (bird flu) study. BlueWillow aims to transform vaccine delivery and efficacy for respiratory and other mucosal pathogens by enabling needle-free, self-administered vaccines that can block infection and transmission.

Infectious DiseasePandemic Preparedness

Technology Platform

NanoVax® platform featuring the W805EC oil-in-water emulsion adjuvant for intranasal delivery. Designed to elicit a balanced mucosal, systemic, and Th1-dominant cellular immune response. Compatible with a wide array of viral, bacterial, and food antigens.

Funding History

21
Total raised:$35.6M
Grant$892K
Grant$873K
Grant$988K
Grant$854K

Opportunities

The platform addresses major needs in pandemic preparedness for pathogens like avian flu, where blocking transmission is key.
It also targets the large seasonal flu market with a needle-free, potentially more effective alternative.
The technology's simplicity could improve vaccine access in low-resource settings.

Risk Factors

The company faces significant clinical development and regulatory risk as it advances its novel intranasal adjuvant platform.
As a private, pre-revenue firm, it is highly dependent on securing additional financing to fund expensive late-stage trials.
It also operates in a competitive landscape with larger players developing mucosal vaccines.

Competitive Landscape

BlueWillow competes in the emerging field of intranasal/mucosal vaccines. Competitors include other biotechs and large pharma companies developing nasal spray vaccines for flu, COVID-19, and other pathogens. BlueWillow's differentiation lies in its clinically validated adjuvant designed specifically for intranasal use to drive a comprehensive immune response.

More companies in Biologics / Biosimilars →More companies in United States →